Prime Capital Investment Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Prime Capital Investment Advisors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Sell	3,938 -33	-0.8%	-$2.48K	﹤0.01%	850
2026 Q1	$298K	Sell	3,971 -10	-0.3%	-$789	﹤0.01%	833
2025 Q4	$315K	Buy	3,981 +47	+1%	+$3.54K	﹤0.01%	796
2025 Q3	$257K	Buy	+3,934	New	+$192K	﹤0.01%	850
2019 Q4	–	Sell	-158	Closed	-$9K	–	611
2019 Q3	$9K	Buy	+158	New	+$10.3K	﹤0.01%	535

Other funds holding IONS

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Prime Capital Investment Advisors's IONS Position: Q2 2026 in Review

Prime Capital Investment Advisors reduced its Ionis Pharmaceuticals (IONS) stake by 0.83% in Q2 2026, selling an estimated $2.48K and leaving 3,938 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Prime Capital Investment Advisors first reported a position in IONS in Q3 2019 and has held it in 5 quarters since. The position peaked at $315K in Q4 2025. 318 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Prime Capital Investment Advisors held 3,938 shares of Ionis Pharmaceuticals worth $312K as of Q2 2026.
Prime Capital Investment Advisors sold 33 Ionis Pharmaceuticals shares in Q2 2026, an estimated $2.48K.
Ionis Pharmaceuticals made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #850 holding.
Prime Capital Investment Advisors first reported a position in Ionis Pharmaceuticals in Q3 2019 and has held it in 5 quarters since.
Prime Capital Investment Advisors's Ionis Pharmaceuticals position peaked at $315K in Q4 2025.
318 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.